IDEAYA Biosciences’ (IDYA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report issued on Monday,Benzinga reports.

A number of other research analysts have also recently weighed in on the stock. Leerink Partnrs cut shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $27.00 in a report on Tuesday, November 5th. Oppenheimer restated an “outperform” rating and set a $53.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Finally, UBS Group assumed coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price for the company. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $23.26 on Monday. The firm has a fifty day moving average of $26.61 and a 200-day moving average of $32.47. IDEAYA Biosciences has a 52-week low of $22.17 and a 52-week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period in the previous year, the company posted ($0.46) EPS. As a group, analysts anticipate that IDEAYA Biosciences will post -2.45 EPS for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in IDYA. Allworth Financial LP increased its position in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 800 shares during the last quarter. Covestor Ltd increased its holdings in IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares during the last quarter. Quest Partners LLC acquired a new stake in IDEAYA Biosciences during the second quarter valued at approximately $41,000. US Bancorp DE lifted its holdings in IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after buying an additional 689 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock worth $68,000 after acquiring an additional 1,684 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.